1. Home
  2. TKC vs ORKA Comparison

TKC vs ORKA Comparison

Compare TKC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turkcell Iletisim Hizmetleri AS

TKC

Turkcell Iletisim Hizmetleri AS

HOLD

Current Price

$5.57

Market Cap

4.9B

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$91.19

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKC
ORKA
Founded
1993
2004
Country
Turkey
United States
Employees
N/A
68
Industry
Telecommunications Equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.5B
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TKC
ORKA
Price
$5.57
$91.19
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$92.50
AVG Volume (30 Days)
2.2M
1.3M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
2.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$31.20
N/A
Revenue Next Year
$24.27
N/A
P/E Ratio
$26.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.35
$12.84
52 Week High
$7.18
$97.78

Technical Indicators

Market Signals
Indicator
TKC
ORKA
Relative Strength Index (RSI) 37.55 59.84
Support Level $5.54 $80.94
Resistance Level $6.07 $97.78
Average True Range (ATR) 0.09 4.97
MACD -0.02 -0.32
Stochastic Oscillator 16.51 69.26

Price Performance

Historical Comparison
TKC
ORKA

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Share on Social Networks: